AstraZeneca plc Receives Average Recommendation of "Hold" from Analysts
Shares of AstraZeneca plc have been given an average rating of "Hold" by the twenty-two ratings firms that are currently covering the stock, Stock Ratings News reports .
Mon Aug 25, 2014
Burger King And Tim Hortons: If You Can't Beat Them, Join Them
Immediate synergy in shared expertise in BKW gains breakfast expertise from THI and THI can leverage BKW for global expansion.
Sat Aug 23, 2014
Competition And Momentum Weighing On Clovis Oncology
Analysts and investors have started fretting that AstraZeneca's drug will be a stronger potential rival to Clovis's lead drug rociletinib.
Fri Aug 22, 2014
AstraZeneca plc Stock Rating Reaffirmed by Deutsche Bank
A number of other analysts have also recently weighed in on AZN. Analysts at Beaufort Securities reiterated a "hold" rating on shares of AstraZeneca plc in a research note on Friday.
Panmure Gordon Reiterates Hold Rating for AstraZeneca plc
AstraZeneca plc traded down 0.19% during mid-day trading on Friday, hitting $73.05.
Beaufort Securities Reiterates "Hold" Rating for AstraZeneca plc
Several other analysts have also recently commented on the stock. Analysts at Credit Suisse reiterated a "neutral" rating on shares of AstraZeneca plc in a research note on Thursday, August 14th.
Thu Aug 21, 2014
Nektar Therapeutics Has More To Give
Investors should know within a month whether the FDA will approve Movantik, Nektar's opioid-induced constipation drug partnered with AstraZeneca that has $1B+ potential.
Pfizer Inc. Eyes Possible Actavis Bid Whilst Weighing Next Steps Over AstraZeneca PLC
Pfizer Inc. isn't giving up on striking an overseas takeover to cut its tax rate and gain a new pipeline of drugs, even as the potential cost of acquiring AstraZeneca Plc rises.
Astrazeneca Announces Partnership with Illumina to Develop Next...
In the first instance, intends to apply Illumina's cutting-edge technology to a novel companion diagnostic test in pivotal studies for one of its investigational oncology compounds.
London close: Astrazeneca leads FTSE higher on bid speculation
Increased speculation regarding ECB action, on the heels of weaker than forecast readings on the Eurozone economy, were offset by a weak report on UK retail sales.
Why AstraZeneca (AZN) Stock Is Higher Today
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
AstraZeneca plc Receives "Hold" Rating from Beaufort Securities
AstraZeneca plc opened at 4375.50 on Thursday. AstraZeneca plc has a 52 week low of GBX 3086.50 and a 52 week high of GBX 5750.00.
Customer Interaction Solutions
Illumina Announces Strategic Partnerships with AstraZeneca, Janssen...
The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine.
Wed Aug 20, 2014
AstraZeneca PLC, Mitsubishi Tanabe Pharma Corporation Link Up For Diabetes Research
AstraZeneca and Mitsubishi Tanabe Pharma said on Wednesday they said signed a three-year research collaboration into diabetic nephropathy, or kidney failure due to diabetes.
Customer Interaction Solutions
Clinigen Group Further Strengthens Oncology Support Portfolio with...
Clinigen Group plc the specialty global pharmaceutical company today announces the acquisition of the global rights to the oncology support therapy, Ethyol from AstraZeneca.
Tue Aug 19, 2014
The Zacks Analyst Blog Highlights: Tesla Motors, CarMax,...
Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
The Negative Impact Of Pfizer's Mergers And Budget Cuts On Cancer R&D
"And then, I don't know if Mikael Dolsten is on the call, but just a question on business development, analyzing, outlicensing activity.
How Will AstraZeneca (AZN) Stock Respond To U.S. Clearing Heart Drug Trial?
The company said the government was closing its investigation into the 18,000-patient study and no further action was planned.
Mon Aug 18, 2014
Us Doj Closes Investigation into Plato
UNITED STATES DEPARTMENT OF JUSTICE CLOSES INVESTIGATION INTO PLATO CLINICAL TRIAL FOR BRILINTA AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta .
Recent Analysts' Ratings Updates for AstraZeneca plc
A number of stock research firms have changed their ratings and price targets for AstraZeneca plc during the last seven days: AstraZeneca plc had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..